Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Calcified Tissue International
Erschienen in: Calcified Tissue International 3/2019

13.06.2019 | Review

The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics

verfasst von: Luc Rochette, Alexandre Meloux, Eve Rigal, Marianne Zeller, Gabriel Malka, Yves Cottin, Catherine Vergely

Erschienen in: Calcified Tissue International | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Osteoporosis (OP) and cardiovascular diseases (CVD) are both important causes of mortality and morbidity in aging patients. There are common mechanisms underlying the regulation of bone remodeling and the development of smooth muscle calcification; a temporal relationship exists between osteoporosis and the imbalance of mineral metabolism in the vessels. Vascular calcification appears regulated by mechanisms that include both inductive and inhibitory processes. Multiple factors are implicated in both bone and vascular metabolism. Among these factors, the superfamily of tumor necrosis factor (TNF) receptors including osteoprotegerin (OPG) and its ligands has been established. OPG is a soluble decoy receptor for receptor activator of nuclear factor-kB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). OPG binds to RANKL and TRAIL, and inhibits the association with their receptors, which have been labeled as the receptor activator of NF-kB (RANK). Sustained release of OPG from vascular endothelial cells (ECs) has been demonstrated in response to inflammatory proteins and cytokines, suggesting that OPG/RANKL/RANK system plays a modulatory role in vascular injury and inflammation. For the development of potential therapeutic strategies targeting vascular calcification, critical consideration of the implications for bone metabolism must be taken into account to prevent potentially detrimental effects to bone metabolism.
Literatur
1.
2.
3.
Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C (2018) The role of osteoprotegerin in the crosstalk between vessels and bone: its potential utility as a marker of cardiometabolic diseases. Pharmacol Ther 182:115–132CrossRefPubMed
4.
Barbu CG, Arsene AL, Florea S, Albu A, Sirbu A, Martin S, Nicolae AC, Burcea-Dragomiroiu GTA, Popa DE, Velescu BS, Dumitrescu IB, Mitrea N, Draganescu D, Lupuliasa D, Spandidos DA, Tsatsakis AM, Dragoi CM, Fica S (2017) Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker. Mol Med Rep 16:6059–6067CrossRefPubMedPubMedCentral
5.
6.
Chung CP, Solus JF, Oeser A, Li C, Raggi P, Smith JR, Stein CM (2015) A variant in the osteoprotegerin gene is associated with coronary atherosclerosis in patients with rheumatoid arthritis: results from a candidate gene study. Int J Mol Sci 16:3885–3894CrossRefPubMedPubMedCentral
7.
8.
Martin-Ventura JL, Munoz-Garcia B, Egido J, Blanco-Colio LM (2007) Trail and vascular injury. Front Biosci 12:3656–3667CrossRefPubMed
9.
Harper E, Forde H, Davenport C, Rochfort KD, Smith D, Cummins PM (2016) Vascular calcification in type-2 diabetes and cardiovascular disease: integrative roles for OPG, RANKL and TRAIL. Vasc Pharmacol 82:30–40CrossRef
10.
Ikeda T, Kasai M, Utsuyama M, Hirokawa K (2001) Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142:1419–1426CrossRefPubMed
11.
Forde H, Harper E, Davenport C, Rochfort KD, Wallace R, Murphy RP, Smith D, Cummins PM (2016) The beneficial pleiotropic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) within the vasculature: a review of the evidence. Atherosclerosis 247:87–96CrossRefPubMed
12.
D’Auria F, Centurione L, Centurione MA, Angelini A, Di Pietro R (2015) Tumor necrosis factor related apoptosis inducing ligand (Trail) in endothelial response to biomechanical and biochemical stresses in arteries. J Cell Biochem 116:2427–2434CrossRefPubMed
13.
Cunha DA, Cito M, Carlsson PO, Vanderwinden JM, Molkentin JD, Bugliani M, Marchetti P, Eizirik DL, Cnop M (2016) Thrombospondin 1 protects pancreatic beta-cells from lipotoxicity via the PERK-NRF2 pathway. Cell Death Differ 23:1995–2006CrossRefPubMedPubMedCentral
14.
Milanova V, Ivanovska N, Dimitrova P (2014) TLR2 elicits IL-17-mediated RANKL expression, IL-17, and OPG production in neutrophils from arthritic mice. Mediators Inflamm 2014:643406CrossRefPubMedPubMedCentral
15.
Kim JY, Park YJ, Kim KJ, Choi JJ, Kim WU, Cho CS (2013) Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress. Arthritis Rheum 65:2172–2182CrossRefPubMed
16.
Lee J, Lee S, Lee CY, Seo HH, Shin S, Choi JW, Kim SW, Park JC, Lim S, Hwang KC (2017) Adipose-derived stem cell-released osteoprotegerin protects cardiomyocytes from reactive oxygen species-induced cell death. Stem Cell Res Ther 8:195CrossRefPubMedPubMedCentral
17.
18.
Rochette L, Lorin J, Zeller M, Guilland JC, Lorgis L, Cottin Y, Vergely C (2013) Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther 140:239–257CrossRefPubMed
19.
Culic O, Gruwel ML, Schrader J (1997) Energy turnover of vascular endothelial cells. Am J Physiol 273:C205–C213CrossRefPubMed
20.
Schoors S, Bruning U, Missiaen R, Queiroz KC, Borgers G, Elia I, Zecchin A, Cantelmo AR, Christen S, Goveia J, Heggermont W, Godde L, Vinckier S, Van Veldhoven PP, Eelen G, Schoonjans L, Gerhardt H, Dewerchin M, Baes M, De Bock K, Ghesquiere B, Lunt SY, Fendt SM, Carmeliet P (2015) Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520:192–197CrossRefPubMedPubMedCentral
21.
Iso T, Maeda K, Hanaoka H, Suga T, Goto K, Syamsunarno MR, Hishiki T, Nagahata Y, Matsui H, Arai M, Yamaguchi A, Abumrad NA, Sano M, Suematsu M, Endo K, Hotamisligil GS, Kurabayashi M (2013) Capillary endothelial fatty acid binding proteins 4 and 5 play a critical role in fatty acid uptake in heart and skeletal muscle. Arterioscler Thromb Vasc Biol 33:2549–2557CrossRefPubMedPubMedCentral
22.
Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, van Meeteren LA, Samen E, Lu L, Vanwildemeersch M, Klar J, Genove G, Pietras K, Stone-Elander S, Claesson-Welsh L, Yla-Herttuala S, Lindahl P, Eriksson U (2010) Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464:917–921CrossRefPubMed
23.
Ingwall JS (2009) Energy metabolism in heart failure and remodelling. Cardiovasc Res 81:412–419CrossRefPubMed
24.
Ashrafian H, Frenneaux MP, Opie LH (2007) Metabolic mechanisms in heart failure. Circulation 116:434–448CrossRefPubMed
25.
Kobayashi-Sakamoto M, Hirose K, Isogai E, Chiba I (2004) NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem Biophys Res Commun 315:107–112CrossRefPubMed
26.
Kobayashi-Sakamoto M, Isogai E, Hirose K, Chiba I (2008) Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation. Microvasc Res 76:139–144CrossRefPubMed
27.
Lommi JI, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Kupari M, Helske S (2011) High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. Atherosclerosis 219:538–544CrossRefPubMed
28.
Rochette L, Zeller M, Cottin Y, Vergely C (2014) Diabetes, oxidative stress and therapeutic strategies. Biochim Biophys Acta 1840:2709–2729CrossRefPubMed
29.
Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, Chen YE (2002) PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 521:180–184CrossRefPubMed
30.
Kleemann R, Bureeva S, Perlina A, Kaput J, Verschuren L, Wielinga PY, Hurt-Camejo E, Nikolsky Y, van Ommen B, Kooistra T (2011) A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis. BMC Syst Biol 5:125CrossRefPubMedPubMedCentral
31.
Stangl K, Stangl V (2010) The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc Res 85:281–290CrossRefPubMed
32.
Laina A, Stellos K, Stamatelopoulos K (2017) Vascular ageing: Underlying mechanisms and clinical implications. Exp Gerontol 109:16–30CrossRefPubMed
33.
Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114:1821–1828CrossRefPubMed
34.
Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111:2461–2468CrossRefPubMed
35.
di Giuseppe R, Biemann R, Wirth J, Menzel J, Isermann B, Stangl GI, Fritsche A, Boeing H, Schulze MB, Weikert C (2017) Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study. Eur J Epidemiol 32:113–123CrossRefPubMed
36.
Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, Lee SY, Kong YY, Kwon YG (2003) Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 278:39548–39557CrossRefPubMed
37.
Potente M, Carmeliet P (2017) The link between angiogenesis and endothelial metabolism. Annu Rev Physiol 79:43–66CrossRefPubMed
38.
Kobayashi-Sakamoto M, Isogai E, Holen I (2010) Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells. Eur J Haematol 85:26–35PubMed
39.
Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18:326–335CrossRefPubMed
40.
Hwang HJ, Jung SH, Lee HC, Han NK, Bae IH, Lee M, Han YH, Kang YS, Lee SJ, Park HJ, Ko YG, Lee JS (2016) Identification of novel therapeutic targets in the secretome of ionizing radiation induced senescent tumor cells. Oncol Rep 35:841–850CrossRefPubMed
41.
Katsimpardi L, Litterman NK, Schein PA, Miller CM, Loffredo FS, Wojtkiewicz GR, Chen JW, Lee RT, Wagers AJ, Rubin LL (2014) Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science 344:630–634CrossRefPubMedPubMedCentral
42.
Rochette L, Zeller M, Cottin Y, Vergely C (2015) Growth and differentiation factor 11 (GDF11): functions in the regulation of erythropoiesis and cardiac regeneration. Pharmacol Ther 156:26–33CrossRefPubMed
43.
Liu W, Zhou L, Zhou C, Zhang S, Jing J, Xie L, Sun N, Duan X, Jing W, Liang X, Zhao H, Ye L, Chen Q, Yuan Q (2016) GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation. Nat Commun 7:12794CrossRefPubMedPubMedCentral
44.
Luo J, Yang Z, Ma Y, Yue Z, Lin H, Qu G, Huang J, Dai W, Li C, Zheng C, Xu L, Chen H, Wang J, Li D, Siwko S, Penninger JM, Ning G, Xiao J, Liu M (2016) LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med 22:539–546CrossRefPubMed
45.
Weitzmann MN, Ofotokun I (2016) Physiological and pathophysiological bone turnover—role of the immune system. Nat Rev 12:518–532
46.
Goltzman D, Mannstadt M, Marcocci C (2018) Physiology of the calcium-parathyroid hormone-vitamin D axis. Front Horm Res 50:1–13CrossRefPubMed
47.
Akbari S, Rasouli-Ghahroudi AA (2018) Vitamin K and bone metabolism: a review of the latest evidence in preclinical studies. Biomed Res Int 2018:4629383CrossRefPubMedPubMedCentral
48.
49.
Roumeliotis S, Dounousi E, Eleftheriadis T, Liakopoulos V (2019) Association of the inactive circulating matrix Gla protein with vitamin K intake, calcification, mortality, and cardiovascular disease: a review. Int J Mol Scie 20:628CrossRef
50.
Lok ZSY, Lyle AN (2019) Osteopontin in Vascular Disease. Arterioscler Thromb Vasc Biol:ATVBAHA118311577
51.
Back M, Aranyi T, Cancela ML, Carracedo M, Conceicao N, Leftheriotis G, Macrae V, Martin L, Nitschke Y, Pasch A, Quaglino D, Rutsch F, Shanahan C, Sorribas V, Szeri F, Valdivielso P, Vanakker O, Kempf H (2018) Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST action EuroSoftCalcNet. Front Cardiovasc Med 5:196CrossRefPubMed
52.
Yiu AJ, Callaghan D, Sultana R, Bandyopadhyay BC (2015) Vascular calcification and stone disease: a new look towards the mechanism. J Cardiovasc Dev Dis 2:141–164CrossRefPubMedPubMedCentral
53.
Davaine JM, Quillard T, Brion R, Laperine O, Guyomarch B, Merlini T, Chatelais M, Guilbaud F, Brennan MA, Charrier C, Heymann D, Goueffic Y, Heymann MF (2014) Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability. PLoS ONE 9:e107642CrossRefPubMedPubMedCentral
54.
Navarro R, Compte M, Alvarez-Vallina L, Sanz L (2016) Immune regulation by pericytes: modulating innate and adaptive immunity. Front Immunol 7:480CrossRefPubMedPubMedCentral
55.
Hung CF, Mittelsteadt KL, Brauer R, McKinney BL, Hallstrand TS, Parks WC, Chen P, Schnapp LM, Liles WC, Duffield JS, Altemeier WA (2017) Lung pericyte-like cells are functional interstitial immune sentinel cells. Am J Physiol 312:L556–L567
56.
Wu M, Rementer C, Giachelli CM (2013) Vascular calcification: an update on mechanisms and challenges in treatment. Calcif Tissue Int 93:365–373CrossRefPubMedPubMedCentral
57.
Schneeweis LA, Willard D, Milla ME (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 280:41155–41164CrossRefPubMed
58.
Garcia-Sanchez C, Posadas-Romero C, Posadas-Sanchez R, Carreon-Torres E, Rodriguez-Perez JM, Juarez-Rojas JG, Martinez-Sanchez C, Fragoso JM, Gonzalez-Pacheco H, Vargas-Alarcon G, Perez-Mendez O (2015) Low concentrations of phospholipids and plasma HDL cholesterol subclasses in asymptomatic subjects with high coronary calcium scores. Atherosclerosis 238:250–255CrossRefPubMed
59.
Wang JC, Bennett M (2012) Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111:245–259CrossRefPubMed
60.
Tziakas DN, Chalikias G, Pavlaki M, Kareli D, Gogiraju R, Hubert A, Bohm E, Stamoulis P, Drosos I, Kikas P, Mikroulis D, Giatromanolaki A, Georgiadis GS, Konstantinou F, Argyriou C, Munzel T, Konstantinides SV, Schafer K (2019) Lysed erythrocyte membranes promote vascular calcification: possible role of erythrocyte-derived nitric oxide. Circulation 139:2032–2048CrossRefPubMed
61.
Tesauro M, Mauriello A, Rovella V, Annicchiarico-Petruzzelli M, Cardillo C, Melino G, Di Daniele N (2017) Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med 281:471–482CrossRefPubMed
62.
Saliques S, Teyssier JR, Vergely C, Lorgis L, Lorin J, Donzel A, Sicard P, Berchoud J, Ragot S, Touzery C, Cottin Y, Rochette L, Zeller M (2011) Smoking and FOS expression from blood leukocyte transcripts in patients with coronary artery disease. Atherosclerosis 219:931–936CrossRefPubMed
63.
Jilka RL, O’Brien CA (2016) The role of osteocytes in age-related bone loss. Curr Osteoporos Rep 14:16–25CrossRefPubMed
64.
Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, Raichle ME, Buckner RL (2007) Disruption of large-scale brain systems in advanced aging. Neuron 56:924–935CrossRefPubMedPubMedCentral
65.
Weiskopf D, Weinberger B, Grubeck-Loebenstein B (2009) The aging of the immune system. Transpl Int 22:1041–1050CrossRefPubMed
66.
Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R, Klaere S, Komnenovic V, Mimata H, Yoshimatsu H, Takahashi N, von Haeseler A, Bader M, Kilic SS, Ueta Y, Pifl C, Narumiya S, Penninger JM (2009) Central control of fever and female body temperature by RANKL/RANK. Nature 462:505–509CrossRefPubMed
67.
Shimamura M, Nakagami H, Osako MK, Kurinami H, Koriyama H, Zhengda P, Tomioka H, Tenma A, Wakayama K, Morishita R (2014) OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. Proc Natl Acad Sci USA 111:8191–8196CrossRefPubMedPubMedCentral
68.
Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179–192CrossRefPubMed
69.
Yamada S, Giachelli CM (2017) Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho. Bone 100:87–93CrossRefPubMed
70.
71.
72.
Pietrzyk B, Smertka M, Chudek J (2017) Sclerostin: intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med 26:1283–1291CrossRefPubMed
73.
Alique M, Ramirez-Carracedo R, Bodega G, Carracedo J, Ramirez R (2018) Senescent microvesicles a novel advance in molecular mechanisms of atherosclerotic calcification. Int J Mol Sci 19(7):2003CrossRefPubMedCentral
74.
Shanahan CM (2013) Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol 9:661–670CrossRefPubMed
75.
Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W (2016) Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis 252:106–115CrossRefPubMed
76.
Wu MY, Li CJ, Yiang GT, Cheng YL, Tsai AP, Hou YT, Ho YC, Hou MF, Chu PY (2018) Molecular regulation of bone metastasis pathogenesis. Cell Physiol Biochem 46:1423–1438CrossRefPubMed
77.
Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massague J, Kang Y (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20:701–714CrossRefPubMedPubMedCentral
78.
79.
Kondegowda NG, Fenutria R, Pollack IR, Orthofer M, Garcia-Ocana A, Penninger JM, Vasavada RC (2015) Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-kappaB ligand pathway. Cell Metab 22:77–85CrossRefPubMedPubMedCentral
80.
Shirakawa J, Togashi Y, Sakamoto E, Kaji M, Tajima K, Orime K, Inoue H, Kubota N, Kadowaki T, Terauchi Y (2013) Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells. Diabetes 62:3448–3458CrossRefPubMedPubMedCentral
81.
Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, Hara A, Toyoda Y, Miwa I, Aizawa S, Tsutsumi S, Tsubamoto Y, Hashimoto S, Eto K, Nakamura A, Noda M, Tobe K, Aburatani H, Nagai R, Kadowaki T (2007) Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117:246–257CrossRefPubMedPubMedCentral
82.
Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S, Coll B, Fernandez E, Valdivielso JM (2009) RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104:1041–1048CrossRefPubMed
83.
de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR (2018) The anti-tumor effect of RANKL inhibition in malignant solid tumors—a systematic review. Cancer Treat Rev 62:18–28CrossRefPubMed
84.
Murakami K, Kobayashi Y, Uehara S, Suzuki T, Koide M, Yamashita T, Nakamura M, Takahashi N, Kato H, Udagawa N, Nakamura Y (2017) A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE 12:e0181126CrossRefPubMedPubMedCentral
85.
Evans BA, Elford C, Pexa A, Francis K, Hughes AC, Deussen A, Ham J (2006) Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. J Bone Miner Res 21:228–236CrossRefPubMed
86.
St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D, Siegenthaler MP, Arduino C, Mancini C, Freudenthal B, Stanescu HC, Zdebik AA, Chaganti RK, Nussbaum RL, Kleta R, Gahl WA, Boehm M (2011) NT5E mutations and arterial calcifications. N Engl J Med 364:432–442CrossRefPubMedPubMedCentral
87.
88.
Patel JJ, Zhu D, Opdebeeck B, D’Haese P, Millan JL, Bourne LE, Wheeler-Jones CPD, Arnett TR, MacRae VE, Orriss IR (2018) Inhibition of arterial medial calcification and bone mineralization by extracellular nucleotides: the same functional effect mediated by different cellular mechanisms. J Cell Physiol 233:3230–3243CrossRefPubMed
89.
Metadaten
Titel
The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics
verfasst von
Luc Rochette
Alexandre Meloux
Eve Rigal
Marianne Zeller
Gabriel Malka
Yves Cottin
Catherine Vergely
Publikationsdatum
13.06.2019
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 3/2019
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-019-00573-6

Weitere Artikel der Ausgabe 3/2019

Calcified Tissue International 3/2019 Zur Ausgabe

Original Research

Cost-Effectiveness of the Screening for the Primary Prevention of Fragility Hip Fracture in Spain Using FRAX®

Original Research

Increased Cellular Presence After Sciatic Neurectomy Improves the Bone Mechano-adaptive Response in Aged Mice

Original Research

No Signature of Osteocytic Osteolysis in Cortical Bone from Lactating NMRI Mice

Original Research

Recombinant Human Bone Morphogenetic Protein 7 Exerts Osteo-Catabolic Effects on Bone Grafts That Outweigh Its Osteo-Anabolic Capacity

Review

MicroRNAs Involved in the Regulation of Angiogenesis in Bone Regeneration

Original Research

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise